Acute myelogenous leukemia (AML), a disease for which treatment has remained relatively unchanged for the past 30 years, is the subject of a new clinical trial featuring a... | [more]
Welcome to Dana-Farber/Harvard Cancer Center
Dana-Farber/Harvard Cancer Center (DF/HCC) is the largest comprehensive cancer center in the world, bringing together the cancer research efforts of our seven member institutions: Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Children’s Hospital Boston, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, and Massachusetts General Hospital.Funded by a grant from the National Cancer Institute, we have joined these seven renowned Harvard-affiliated medical centers into one collective force dedicated to the fight against cancer. Based in Boston, DF/HCC consists of more than 1,000 researchers with a singular goal — to find new and innovative ways to combat cancer.
Announcements
- The Role of the Jak/Stat Pathway in Mitochondrial Function Posted: 02-04-10
- Dana-Farber Cancer Institute and DF/HCC Seminars in Oncology Posted: 01-29-10
- Including Clinical Trials in Your Practice Posted: 01-22-10
Latest Cancer News
Bortezomib denies leukemia stem cell development
Delivering a one-two punch to the PI3K signaling pathway
Based largely on original research from a team of DF/HCC investigators, a new clinical trial has launched to determine if combination therapy with a tyrosine kinase inhibitor... | [more]
Co-clinical mouse/human trials aim to speed up drug approvals
The many breakthroughs in understanding the pathways involved in leukemia have delivered a double-edged sword: hundreds of new drugs await testing but an insufficient patient... | [more]
Functional genomics yields drivers, mutations, and pathways in leukemia
The study of genes, mutations, and collective pathways contributing to leukemia is a cornerstone of the DF/HCC Leukemia Program, led by Thomas Look (DFCI). The mutations that... | [more]
